COVID-19 rapid guideline: delivery of systemic anticancer treatments- updated guideline (NG161)

Recommendation 7.2 has been amended so deferring treatments that prevent long-term complications is no longer recommended and subcutaneous medicines has been added to the medicines that can be provided by home delivery.

National Institute for Health and Care Excellence